News and Comments

Who Skipped the Bloody Market? Why Gilead Embarked on Galapagos NV Drug Filgotonib?

  Monday, January 04, 2016

The market looks like angry, probably very angry, as stocks are in a severe selloff mood. There will be many explanations like usual, but it is difficult for us to speculate this time over the correctness of the offered explanations, including the Iran Saudi Arabia crisis, which led to an increase in the oil price whose decrease has caused the previous market’s bad mood.    More...

ARRAY Rallies on Successful NEMO Trial Results of Binetinib on NRAS-Mutant Melanoma

  Wednesday, December 16, 2015

When you do your due diligence, you do not lose your faith in what you believed in giving up to the hype that’s sprayed around you. We were happy today to hear Array BioPharma (ARRY) report that results from the Phase 3 NEMO clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma. The trial met its primary endpoints.  More...

Halozyme PEGPH20 Improves the Efficacy of Halavan In Triple Negative Breast Cancer

  Thursday, December 10, 2015

Halozyme Therapeutics (HALO) and Eisai Inc. presented a scientific poster entitled, "Pegylated Recombinant Human Hyaluronidase PH20 (PEGPH20) Enhances Efficacy of Eribulin Mesylate (HALAVEN®) in Triple Negative Breast Cancer Xenografts" at the 38th Annual San Antonio Breast Cancer Symposium (SABCS).   More...

XOMA: Good News for the Firm We Love and Hate but We Never Divorce

  Wednesday, December 02, 2015

XOMA Announces License Agreement with Novo Nordisk for XMetA Program in Diabetes  More...

BIOMARIN: What Happened During the FDA Committee Meeting?

  Wednesday, November 25, 2015


Biomarin: The DMD Drug and the FDA Committee Options

  Tuesday, November 24, 2015

Today, the FDA advisory panel will discuss BioMarin (BMRN) product drisapersen for Duchenne muscular dystrophy based on documents released to the committee by the FDA. The FDA said, “The benefit of drisapersen in exon 51 skip amenable patients is inconclusive at this time. Therefore, the benefit-risk assessments were not made.”  More...

VERTEX: Orkambi Approved In Europe. What Vertex is Doing to Further improve CF Treatments

  Friday, November 20, 2015

Europe Approves Orkambi®  More...

Ziopharm Wages Its Own War On Brain Cancer

  Thursday, November 19, 2015

When we hear about a new approach that promises bringing in hopefulness in patients diagnosed with brain glioma, we try to listen and hope for the best, rather than develop and demonstrate  skepticism. Are we not walking the road of genetic engineering, gene therapy approaches and immunotherapy? Our optimism becomes realistic, especially when a scientific rationale is explained by researchers in scientifically solid firms that are specialized in cancer treatment with novel breakthrough methods.  More...

Aimmune Therapeutics: Oral Peanut desensitization Treatment is Promising

  Wednesday, November 11, 2015

Food allergies are bad, significant, dangerous and growing in the U.S. and the rest of the world. More than 30 million people in the United States and Europe have a food allergy, and more than five million people in the United States and Europe have peanut allergy, including more than two million children.  More...

Exelixis Will Begin Reaping the Fruits

  Tuesday, November 10, 2015


Recent Postings



CRISPR Therapeutics (CRSP) Genentech Array Pharmaceuticals (ARRY) Roche (RHHBY) Dynavax (DVAX) Seattle Genetics (SGEN) Biocryst (BCRX) Multiple Myeloma Aimmune Therapeutics (AIMT) Adaptimmune (ADAP) Anacor (ANAC) Bristol-Myers Squibb (BMY) Alnylam (ALNY) Ziofpharm (ZIOP) Incyte (INCY) Theravance Bio Pharma (TBPH) AGOS (ARGS) ZALTRAP™ Sangamo (SGMO) BIOMARIN (BMRN) Sanofi (SNA) AstraZeneca (AZN) Benlysta (belimumab) TOKAI (TKAOI) ABBVIE (ABBV) LEXICON (LXRX) Illumina (ILMN) Intermune (ITMN) Elan (ELN) Alder Biopharmaceuticals (ALDR) GUARDIAN HEALTH ARGOS (ARGS) VANDA (VNDA) Gilead (GILD) Vertex (VRTX) Human Genome Sciences (HGSI) Prosensa (RNA) Onyx (ONXX) Sequenom (SQNM) Editas (EDIT) GlaxoSmithKline (GSK) KITE (KITE) JUNO (JUNO) Amgen (AMGN) Revlimid (lenolidamide) IDERA (IDRA) ADVENTRIX (ANX) HALOZYME (HALO) Abbott Laboratories (ABT) SYNTA (SNTA) Prolor Biotech (PBTH) Endometrial Cancer MODERNA CompuGen (CGEN) JOUNCE THERAPEUTICS (JNCE) Dendreon (DNDN) NOVOCURE (NVCR) Idenix (IDIX) OncoCyte (OCX) Sanofi-Aventis (SAN) Auspex (ASPX) Advaxis (ADXS) Theravance (THRX) Regeneron (REGN) Ridaforolimus Ocular Therapeutix (OCUL) ARCA (ABIO) Micromet (MITI) Spike Therapeutics (ONCE) Cytokinetics (CYTK) Valeant Pharmaceuticals International (VRX) Inovio (INO) C4 Therapeutics Telaprevir ACADIA (ACAD) Tysabri REGULUS (RGLS) Agenus (AGEN AERIE PHARMACEUTICALS Mirati Therapeutics (MRTX) ISIS (ISIS) Ariad (ARIA) NANTKWEST (NK) Anadys (ANDS) Velcade (bortezomib) Rapamune Sanofi (SNY) Agenus (AGEN) Bellicum (BLCM) INNOVIVA (INVA) Sarepta (SRPT) Jazz Pharmaceuticals (JAZZ) SUNESIS PHARMACEUTICALS (SNSS) Roche (ROCHE) Galena (GALE) NEKTAR (NKTR)) Trastuzumab-DM1 Pluristem (PSTI) Intrexon (XON) Xoma (XOMA) Biogen Idec (BIIB) Vitae Pharmaceuticals (VTAE) Exelixis (EXEL) Global Cell Therapeutics (GBT) PTC Therapeutics (PTCT) Intercept (ICPT) Zerenex Human Longevity (HLI) OSI (OSIP) SERES THERAPEUTICS (MCRB) PORTOLA (PTLA) Ionis (IONS) galapagos (GLPG) KERYX (KERX) Herceptin ImmunoGen (IMGN) RenenxBio (RGNX) Merck (MRK) CEMPRA (CEMP)